James F. Young - Mar 31, 2022 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
Director
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Mar 31, 2022
Transactions value $
-$919,765
Form type
4
Date filed
4/4/2022, 05:14 PM
Previous filing
Jan 4, 2022
Next filing
Jun 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Sale -$656K -8.95K -11.91% $73.29* 66.1K Mar 31, 2022 Direct F1
transaction NVAX Common Stock Sale -$242K -3.26K -4.92% $74.25* 62.9K Mar 31, 2022 Direct F2
transaction NVAX Common Stock Sale -$22.5K -300 -0.48% $75.10* 62.6K Mar 31, 2022 Direct F3
holding NVAX Common Stock 1.5K Mar 31, 2022 By spouse F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.98 to $73.91, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F2 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.01 to $74.98, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.01 to $75.25, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F4 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.